Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of “Reduce” by Analysts

Moderna, Inc. (NASDAQ:MRNA) has been given an average recommendation of “Reduce” by the nineteen analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $29.4615.

A number of equities research analysts have recently weighed in on MRNA shares. Wolfe Research reiterated an “underperform” rating and issued a $17.00 price objective on shares of Moderna in a research report on Thursday, November 20th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Monday, October 20th. UBS Group reissued a “buy” rating on shares of Moderna in a research report on Friday, November 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a research report on Monday. Finally, Berenberg Bank set a $28.00 price target on shares of Moderna in a research report on Monday, November 17th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. S Bank Fund Management Ltd purchased a new stake in Moderna in the first quarter worth $25,000. Rothschild Investment LLC boosted its holdings in shares of Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in shares of Moderna by 348.8% during the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after buying an additional 743 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new stake in shares of Moderna in the 2nd quarter worth about $26,000. Finally, SVB Wealth LLC bought a new position in shares of Moderna in the 1st quarter worth about $28,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 0.4%

MRNA stock opened at $24.06 on Friday. The stock has a market capitalization of $9.40 billion, a price-to-earnings ratio of -2.98 and a beta of 1.11. The firm’s 50-day moving average price is $25.80 and its two-hundred day moving average price is $26.99. Moderna has a 12-month low of $22.28 and a 12-month high of $48.92.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. During the same period last year, the firm earned $0.03 earnings per share. Moderna’s quarterly revenue was down 45.4% on a year-over-year basis. Equities analysts predict that Moderna will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.